Science Abstracts
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
March 2010
March 2010
Authors : Sharmila Patel , Mark R Player
Affliation : Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA ; ; mplayer@its.jnj.com
DOI : 10.1517/13543780802493366
Published in : Expert Opin. Investig. Drugs
Subject: Review
Keywords: HDM2 , MDM2 , p53 , protein–protein interaction
Abstract
Please Login to read the full article.
RELATED CONTENT
NEWS
- Scottish cell signalling unit forging links with industry
- Boehringer and Priaxon sign €86 million anticancer pact
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- Mixed Phase III results for Erbitux in first-line colorectal cancer
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
